Evidence map›Paper›PMID 42242232›Full record

ArticleCancer cell2026

Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.

Lynda Vuong, Andrew E Cornish, Jennifer Pfeil, Yash Khandwala, Hui Jiang, Doris X T Zheng, Eduardo A Mascareno, Nicole Rittenhouse, Phillip M Rappold, Josef Leibold and 30 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Lynda VuongUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: vuongl@mskcc.org.
Andrew E CornishImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jennifer PfeilLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Yash KhandwalaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hui JiangUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Doris X T ZhengUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eduardo A MascarenoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicole RittenhouseUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Phillip M RappoldUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Josef LeiboldCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany; DFG Cluster of Excellence 2180 Image-Guided and Functional Instructed Tumor Therapy (iFIT), University of Tuebingen, Tuebingen, Germany.
Erich A SabioHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kate WeissUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carlene GonzalezDepartment of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Liangliang JiImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jing ZhangImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mojca AdlesicCentre for Translational Cell Research, University Hospital Freiburg, Freiburg, Germany.
Oguz AkinDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jessica FlynnDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chirag KrishnaComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Inflammation and Immunology Research Unit, Pfizer, Cambridge, MA, USA.
Andrea Lopez SanmiguelUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rebecca A SagerUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tiak J TanLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Alejandro SanchezUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Renzo G Di NataleUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kyle A BlumUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ian J FrewCentre for Translational Cell Research, University Hospital Freiburg, Freiburg, Germany.
Diego ChowellDepartment of Oncological Sciences, The Precision Immunology Institute, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ying-Bei ChenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David B SolitHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Irina OstrovnayaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert J MotzerDepartment of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Martin H VossDepartment of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ritesh R KotechaDepartment of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.
Hartland W JacksonLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Fengshen KuoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ming O LiImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hakimia@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinomaR01CA258886 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HAKIMI, ABRAHAM ARI · 2021 to 2025
$2.4M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA258886
6 · The paper itself

Abstract

Vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors (VEGFR-TKIs) and anti-PD-1 (aPD-1) combinations are effective in multiple solid tumors, particularly in clear cell renal cell carcinoma (ccRCC), due to its characteristic pseudohypoxic, hyper-angiogenic state driven by biallelic VHL loss. However, long-term durability is inferior to dual aPD-1/anti-CTLA-4 regimens, yet the underlying mechanisms remain unclear. We investigated tumor microenvironment evolution following VEGFR-TKI, aPD-1, and combined VEGFR-TKI/aPD-1 treatment in a transgenic ccRCC mouse model. We identify hypoxia-responsive SPP1

Indexed as

Carcinoma, Renal CellDrug Resistance, NeoplasmKidney NeoplasmsAnimalsHumansImmune Checkpoint InhibitorsMiceMice, TransgenicProtein Kinase InhibitorsTumor-Associated MacrophagesTumor HypoxiaTumor MicroenvironmentImmune Checkpoint InhibitorsProtein Kinase Inhibitorsangiogenesis inhibitorsclear cell renal cell carcinomaGPNMBhypoxiaimmune checkpoint blockadepseudohypoxiaSPP1tumor-associated macrophagestumor microenvironmentvascular normalization

Identifiers

PMID42242232
PMCPMC13383571

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.